Remote patient monitoring (RPM) — the use of connected medical devices to collect physiological data from patients in their homes and transmit it to clinical teams for review and response — has completed its transition from research novelty to mainstream clinical practice. Driven by CMS reimbursement codes introduced in 2018 (CPT 99453/99454 for setup and device; 99457/99458 for clinical time), the clinical evidence base is now robust, and health systems ranging from rural critical access hospitals to large academic medical centers are deploying RPM programs for heart failure, hypertension, diabetes, COPD, and post-surgical care. The question has shifted from "does RPM work?" to "what to monitor, how to implement at scale, and how to integrate data into clinical workflow without generating alert fatigue."
Heart Failure: The Evidence Standard
RPM for heart failure has the largest and most consistent evidence base of any RPM indication. Daily weight monitoring with automated alerts for ≥2 lb gain (indicating fluid retention) allows medication adjustment before symptomatic decompensation requiring hospitalization. The CONNECT-HF trial demonstrated 15% reduction in 90-day readmission. Implantable hemodynamic monitoring with the CardioMEMS device (pulmonary artery pressure sensor) demonstrated 28% reduction in 6-month HF hospitalization in the CHAMPION trial — the most powerful single-device evidence in the RPM literature. Non-invasive alternatives including acoustic cardiography (Body Guardian Mini), thoracic impedance (in compatible ICD/CRT devices), and wearable dielectric sensors are expanding the non-implantable monitoring toolkit.
Hypertension: The Highest-Volume Use Case
Hypertension RPM — providing connected blood pressure cuffs with readings transmitted to a clinical care management platform — is the highest-volume RPM application in the United States. Multiple RCTs confirm greater systolic BP reduction with RPM versus clinic-only monitoring (mean difference 6–10 mmHg), driven by more frequent measurement, faster medication titration, and home blood pressure more accurately reflecting true 24-hour BP burden than white-coat-influenced office readings. Programs integrating pharmacist-led protocol-based titration with RPM data achieve BP control rates of 80%+, dramatically exceeding the national 38% control rate. Required device investment for a hypertension RPM program is modest: validated connected blood pressure cuffs costing $40–80 per patient.
Diabetes: CGM and Connected Glucometer Programs
For Type 1 and Type 2 diabetes, continuous glucose monitoring (CGM) data platforms enable endocrinologists and certified diabetes care and education specialists (CDCES) to review 2 weeks of CGM data in a 10-minute virtual visit — identifying time-in-range gaps, hypoglycemic episodes, and mealtime response patterns that drive targeted therapy adjustments. Connected glucometer programs for patients not yet on CGM provide structured glucose logs without the documentation burden of paper diaries. The T1D Exchange Quality Improvement Collaborative achieved mean TIR improvement of 15 percentage points in participating centers implementing standardized CGM data review protocols.
COPD: Reducing the 30-Day Readmission Rate
COPD readmissions — a 23% 30-day rate, representing a $15 billion annual cost — are a prime RPM target. Daily pulse oximetry, respiratory rate monitoring, and symptom surveys via smartphone enable early detection of exacerbations 2–5 days before emergency department presentation. Programs including Propeller Health (inhaler adherence sensing) and Vivify Health COPD pathways demonstrate 40–45% reductions in COPD-related hospitalizations in deployed health systems. Healthcare facilities building RPM infrastructure for COPD management should source respiratory monitoring supplies and pulse oximetry devices compatible with RPM platforms.
